{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:44:47Z","timestamp":1789587887748,"version":"build-2803163510"},"reference-count":30,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Amgen Taiwan Limited"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,21]]},"abstract":"Abstract<\/jats:title>\n \n Context<\/jats:title>\n Despite prevalent anti-osteoporosis medication (AOM) switching in real-world osteoporosis management, few studies have evaluated the impact of persistent AOM treatment, allowing for AOM switching, on the risk of subsequent fracture.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n We examined the association between persistence in AOM and subsequent fractures, allowing for medication switching among patients with osteoporotic fractures.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This retrospective cohort study used Taiwan National Health Insurance claims data to select patients who initiated AOM between 2013 and 2016. Treatment persistence was defined as use of any AOM on a given day of interest with a 45-day grace period. Medication switch was allowed for persistence if remaining on treatment. AOMs with long-lasting inhibition of bone resorption (zoledronate and denosumab) were categorized as high-potency; others as low-potency. Multivariate Cox models were used to evaluate risk of subsequent fractures \u22653 months after initiating AOM.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 119 473 patients were included (mean [SD] follow-up 46.4 [15.6] months), and 26.8% switched from the index AOM. Within 1 year, 52% remained persistent with AOM. Compared to patients with persistent AOM, those not persistent had higher risk of subsequent hip (adjusted hazard ratio [aHR] = 1.31; 95% CI, 1.21-1.42), vertebral (aHR = 1.17; 95% CI, 1.13-1.22), and radius fractures (aHR = 1.16; 95% CI, 1.08-1.25). Patients with persistent AOM who switched from high- to low-potency AOM had higher risk of subsequent vertebral fractures than those with persistent AOM and no potency switch (aHR = 1.28; 95% CI, 1.02-1.60).<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Patients with non-persistent AOM had higher risk of subsequent fractures than persistent users when allowing AOM switch. Switching AOM potency may influence the risk of subsequent vertebral fractures and warrants further investigation.<\/jats:p>\n <\/jats:sec>","DOI":"10.1210\/clinem\/dgad449","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T11:51:31Z","timestamp":1690890691000},"page":"e200-e208","source":"Crossref","is-referenced-by-count":6,"title":["Treatment Persistence and Medication Switch Associated With Subsequent Fractures After Osteoporotic Fractures"],"prefix":"10.1210","volume":"109","author":[{"given":"Sung-Yen","family":"Lin","sequence":"first","affiliation":[{"name":"Orthopaedic Research Center, Kaohsiung Medical University , Kaohsiung 80708 , Taiwan"},{"name":"Department of Orthopedics, Kaohsiung Medical University Hospital, Kaohsiung Medical University , Kaohsiung 80708 , Taiwan"},{"name":"Regeneration Medicine and Cell Therapy Research Center, Kaohsiung Medical University , Kaohsiung 80708 , Taiwan"},{"name":"Division of Adult Reconstruction Surgery, Department of Orthopedics, Kaohsiung Medical University Hospital, Kaohsiung Medical University , Kaohsiung 80708 , Taiwan"},{"name":"Department of Orthopedics, School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University , Kaohsiung 80708 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ju","family":"Chen","sequence":"additional","affiliation":[{"name":"Medical, Amgen Taiwan Limited , Taipei 110 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Ko","family":"Ku","sequence":"additional","affiliation":[{"name":"Medical, Amgen Taiwan Limited , Taipei 110 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, and Rheumatology, Department of Medical Research, Taichung Veterans General Hospital , Taichung 40705 , Taiwan"},{"name":"School of Medicine, College of Medicine, National Yang Ming Chiao Tung University , Taipei 112304 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8941-4792","authenticated-orcid":false,"given":"Chung-Hwan","family":"Chen","sequence":"additional","affiliation":[{"name":"Orthopaedic Research Center, Kaohsiung Medical University , Kaohsiung 80708 , Taiwan"},{"name":"Department of Orthopedics, Kaohsiung Medical University Hospital, Kaohsiung Medical University , Kaohsiung 80708 , Taiwan"},{"name":"Regeneration Medicine and Cell Therapy Research Center, Kaohsiung Medical University , Kaohsiung 80708 , Taiwan"},{"name":"Division of Adult Reconstruction Surgery, Department of Orthopedics, Kaohsiung Medical University Hospital, Kaohsiung Medical University , Kaohsiung 80708 , Taiwan"},{"name":"Department of Orthopedics, School of Medicine, College of Medicine, Kaohsiung Medical University , Kaohsiung 80708 , Taiwan"},{"name":"Department of Orthopedics, Kaohsiung Municipal Ta-Tung Hospital , Kaohsiung 80145 , Taiwan"},{"name":"Ph.D. Program in Biomedical Engineering, College of Medicine, Kaohsiung Medical University , Kaohsiung 80708 , Taiwan"},{"name":"Institute of Medical Science and Technology, National Sun Yat-Sen University , Kaohsiung 80424 , Taiwan"},{"name":"Graduate Institute of Materials Engineering, College of Engineering, National Pingtung University of Science and Technology , Pingtung 912301 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9441-552X","authenticated-orcid":false,"given":"Li-Nien","family":"Chien","sequence":"additional","affiliation":[{"name":"Institute of Health and Welfare Policy, College of Medicine, National Yang Ming Chiao Tung University , Taipei 112304 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"issue":"10","key":"2023122122202998900_dgad449-B1","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"key":"2023122122202998900_dgad449-B2","author":"FDA: U.S. Food and Drug Administration","year":"2019"},{"key":"2023122122202998900_dgad449-B3","author":"International Osteoporosis Foundation","year":"2019"},{"issue":"11","key":"2023122122202998900_dgad449-B4","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s00198-018-4630-6","article-title":"Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis","volume":"29","author":"Liu","year":"2018","journal-title":"Osteoporos Int"},{"issue":"8","key":"2023122122202998900_dgad449-B5","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.clinthera.2019.05.001","article-title":"Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women: a systematic review","volume":"41","author":"Fardellone","year":"2019","journal-title":"Clin Ther"},{"issue":"2","key":"2023122122202998900_dgad449-B6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00198-012-1984-z","article-title":"Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan","volume":"24","author":"Soong","year":"2013","journal-title":"Osteoporos Int"},{"issue":"1","key":"2023122122202998900_dgad449-B7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11657-022-01125-6","article-title":"Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan","volume":"17","author":"Lin","year":"2022","journal-title":"Arch Osteoporos"},{"issue":"12","key":"2023122122202998900_dgad449-B8","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1007\/s00198-021-05951-1","article-title":"Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage","volume":"32","author":"Singer","year":"2021","journal-title":"Osteoporos Int"},{"issue":"1","key":"2023122122202998900_dgad449-B9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/gme.0b013e318221bacd","article-title":"Persistence with osteoporosis medications among postmenopausal women in the UK general practice research database","volume":"19","author":"Li","year":"2012","journal-title":"Menopause"},{"issue":"6","key":"2023122122202998900_dgad449-B10","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/joim.13354","article-title":"Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: a population-based cohort study","volume":"290","author":"Fu","year":"2021","journal-title":"J Intern Med"},{"key":"2023122122202998900_dgad449-B11","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2147\/COPD.S289799","article-title":"Prescription patterns in patients with chronic obstructive pulmonary disease and osteoporosis","volume":"16","author":"Liao","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"2023122122202998900_dgad449-B12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11657-016-0282-3","article-title":"Persistence with denosumab and zoledronic acid among older women: a population-based cohort study","volume":"11","author":"Tremblay","year":"2016","journal-title":"Arch Osteoporos"},{"issue":"7","key":"2023122122202998900_dgad449-B13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 Years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2023122122202998900_dgad449-B14","first-page":"23","article-title":"What do you really need to know about bisphosphonates?","volume":"66","author":"Goodchild","year":"2018","journal-title":"Gen Dent"},{"key":"2023122122202998900_dgad449-B15","author":"Lin","year":"2023"},{"issue":"10","key":"2023122122202998900_dgad449-B16","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/jbmr.3807","article-title":"The design and validation of a new algorithm to identify incident fractures in administrative claims data","volume":"34","author":"Wright","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2023122122202998900_dgad449-B17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4300\/JGME-D-12-00156.1","article-title":"Using effect size-or why the P value is not enough","volume":"4","author":"Sullivan","year":"2012","journal-title":"J Grad Med Educ"},{"issue":"1","key":"2023122122202998900_dgad449-B18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jval.2011.07.010","article-title":"Extension of Kaplan-Meier methods in observational studies with time-varying treatment","volume":"15","author":"Xu","year":"2012","journal-title":"Value Health"},{"issue":"4","key":"2023122122202998900_dgad449-B19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1198\/000313005X70371","article-title":"Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator","volume":"59","author":"Snapinn","year":"2005","journal-title":"Am Stat"},{"issue":"6","key":"2023122122202998900_dgad449-B20","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/joim.13369","article-title":"Stopping osteoporosis medications","volume":"290","author":"Reid","year":"2021","journal-title":"J Intern Med"},{"issue":"1","key":"2023122122202998900_dgad449-B21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2023122122202998900_dgad449-B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-015-3334-4","article-title":"Treatment of osteoporosis after alendronate or risedronate","volume":"27","author":"Eiken","year":"2016","journal-title":"Osteoporos Int"},{"issue":"2","key":"2023122122202998900_dgad449-B23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2023122122202998900_dgad449-B24","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023122122202998900_dgad449-B25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023122122202998900_dgad449-B26","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","article-title":"Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study","volume":"34","author":"Tutaworn","year":"2023","journal-title":"Osteoporos Int"},{"issue":"1","key":"2023122122202998900_dgad449-B27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int"},{"issue":"2","key":"2023122122202998900_dgad449-B28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/14397595.2020.1769895","article-title":"Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis","volume":"31","author":"Ebina","year":"2021","journal-title":"Mod Rheumatol"},{"issue":"5","key":"2023122122202998900_dgad449-B29","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.fertnstert.2019.10.005","article-title":"Human skeletal physiology and factors affecting its modeling and remodeling","volume":"112","author":"Nandiraju","year":"2019","journal-title":"Fertil Steril"},{"issue":"6","key":"2023122122202998900_dgad449-B30","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S8756-3282(02)00735-4","article-title":"Misconceptions (2): turnover is always higher in cancellous than in cortical bone","volume":"30","author":"Parfitt","year":"2002","journal-title":"Bone"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad449\/51076611\/dgad449.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/1\/e200\/54731718\/dgad449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/1\/e200\/54731718\/dgad449.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T22:22:48Z","timestamp":1703197368000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/1\/e200\/7234535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,8,1]]},"published-print":{"date-parts":[[2023,12,21]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad449","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,8,1]]}}}